Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

ClinicalTrials.gov ID: NCT03924947

Public ClinicalTrials.gov record NCT03924947. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 27, 2026, 4:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 4 Study to Compare US Marketed Creon Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site and With Drug Product Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Subjects With EPI Due to Cystic Fibrosis

Study identification

NCT ID
NCT03924947
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
AbbVie
Industry
Enrollment
36 participants

Conditions and interventions

Interventions

  • Pancrelipase Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 22, 2019
Primary completion
Jul 10, 2022
Completion
Jul 10, 2022
Last update posted
Sep 27, 2023

2019 – 2022

United States locations

U.S. sites
13
U.S. states
9
U.S. cities
12
Facility City State ZIP Site status
University of Southern California /ID# 164571 Los Angeles California 90033
Landon Pediatric Foundation /ID# 215411 Ventura California 93003-3099
Nemours Children's Health System /ID# 164553 Jacksonville Florida 32207
Central FL Pulmonary Orlando /ID# 164558 Orlando Florida 32803
The Cystic Fibrosis Institute /ID# 210757 Northfield Illinois 60093
University of Iowa Hospitals and Clinics /ID# 164551 Iowa City Iowa 52242
Via Christi Research /ID# 214266 Wichita Kansas 67214-2878
UH Cleveland Medical Center /ID# 206095 Cleveland Ohio 44106
Cleveland Clinic Main Campus /ID# 212853 Cleveland Ohio 44195
Nationwide Children's Hospital /ID# 225628 Columbus Ohio 43205-2664
Children's Hospital of Philadelphia - Main /ID# 208114 Philadelphia Pennsylvania 19104-4319
Vanderbilt University Medical Center /ID# 213434 Nashville Tennessee 37232-0011
Virginia Commonwealth University Medical Center Main Hospital /ID# 164574 Richmond Virginia 23219

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03924947, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 27, 2023 · Synced Jun 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03924947 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →